Concepts (255)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 6 | 2019 | 117 | 1.500 |
Why?
|
| Arthroplasty, Replacement, Knee | 4 | 2019 | 91 | 1.320 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 51 | 1.270 |
Why?
|
| Pulmonary Embolism | 3 | 2019 | 51 | 1.180 |
Why?
|
| Knee Joint | 2 | 2018 | 143 | 1.060 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2018 | 40 | 1.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2022 | 97 | 0.970 |
Why?
|
| Medicare | 5 | 2022 | 213 | 0.890 |
Why?
|
| Postoperative Complications | 7 | 2022 | 828 | 0.860 |
Why?
|
| Neoplasms | 4 | 2022 | 762 | 0.840 |
Why?
|
| Orthopedics | 2 | 2023 | 94 | 0.840 |
Why?
|
| Humans | 41 | 2024 | 32966 | 0.830 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 754 | 0.700 |
Why?
|
| Case-Control Studies | 7 | 2022 | 880 | 0.700 |
Why?
|
| Retrospective Studies | 13 | 2024 | 3708 | 0.670 |
Why?
|
| Osteosarcoma | 2 | 2019 | 11 | 0.650 |
Why?
|
| United States | 11 | 2023 | 4132 | 0.640 |
Why?
|
| Aged | 16 | 2022 | 10637 | 0.620 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 537 | 0.620 |
Why?
|
| Hemophilia B | 1 | 2019 | 6 | 0.620 |
Why?
|
| Shoulder Joint | 1 | 2022 | 137 | 0.610 |
Why?
|
| Osteoporosis | 1 | 2020 | 71 | 0.610 |
Why?
|
| Sarcoma | 3 | 2018 | 71 | 0.600 |
Why?
|
| Hemophilia A | 1 | 2019 | 26 | 0.600 |
Why?
|
| Middle Aged | 18 | 2024 | 12203 | 0.580 |
Why?
|
| Interpersonal Relations | 1 | 2019 | 58 | 0.570 |
Why?
|
| Teaching | 1 | 2019 | 61 | 0.570 |
Why?
|
| Ascorbic Acid | 1 | 2018 | 21 | 0.550 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 130 | 0.540 |
Why?
|
| Reimbursement Mechanisms | 1 | 2017 | 13 | 0.540 |
Why?
|
| Hip Fractures | 1 | 2017 | 30 | 0.530 |
Why?
|
| Musculoskeletal Diseases | 1 | 2018 | 42 | 0.530 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 4065 | 0.530 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 188 | 0.520 |
Why?
|
| Nutritional Status | 1 | 2017 | 78 | 0.520 |
Why?
|
| Antioxidants | 1 | 2018 | 116 | 0.510 |
Why?
|
| Patient Readmission | 1 | 2017 | 135 | 0.490 |
Why?
|
| Sarcoma, Experimental | 1 | 2016 | 4 | 0.480 |
Why?
|
| Spasm | 1 | 2016 | 6 | 0.480 |
Why?
|
| Fractures, Bone | 1 | 2017 | 162 | 0.480 |
Why?
|
| Male | 18 | 2024 | 19754 | 0.460 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2015 | 34 | 0.440 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 384 | 0.430 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 476 | 0.430 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 72 | 0.430 |
Why?
|
| Angiotensin I | 1 | 2016 | 241 | 0.420 |
Why?
|
| Peptide Fragments | 1 | 2016 | 410 | 0.390 |
Why?
|
| Vascular Malformations | 1 | 2012 | 11 | 0.380 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 9 | 0.370 |
Why?
|
| Diphosphonates | 1 | 2012 | 9 | 0.370 |
Why?
|
| Alendronate | 1 | 2012 | 11 | 0.370 |
Why?
|
| Risk Assessment | 1 | 2017 | 1469 | 0.360 |
Why?
|
| Brachytherapy | 1 | 2012 | 24 | 0.360 |
Why?
|
| Fractures, Stress | 1 | 2012 | 12 | 0.360 |
Why?
|
| Female | 16 | 2024 | 20375 | 0.360 |
Why?
|
| Catheter Ablation | 1 | 2012 | 114 | 0.350 |
Why?
|
| Femoral Fractures | 1 | 2012 | 45 | 0.350 |
Why?
|
| Carbapenems | 1 | 2021 | 7 | 0.350 |
Why?
|
| Cephalosporins | 1 | 2021 | 9 | 0.350 |
Why?
|
| Mouth Mucosa | 1 | 2021 | 30 | 0.340 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 45 | 0.320 |
Why?
|
| Wound Healing | 1 | 2021 | 188 | 0.320 |
Why?
|
| Fasting | 1 | 2020 | 94 | 0.310 |
Why?
|
| Dyslipidemias | 1 | 2020 | 54 | 0.310 |
Why?
|
| Regenerative Medicine | 1 | 2021 | 202 | 0.290 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 24 | 0.270 |
Why?
|
| Secondary Prevention | 2 | 2020 | 65 | 0.270 |
Why?
|
| Adult | 9 | 2024 | 9586 | 0.260 |
Why?
|
| Treatment Outcome | 4 | 2022 | 3460 | 0.260 |
Why?
|
| Cardiology Service, Hospital | 1 | 2017 | 22 | 0.250 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 32 | 0.250 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 424 | 0.250 |
Why?
|
| Animals | 6 | 2022 | 7599 | 0.240 |
Why?
|
| Dystonia | 1 | 2015 | 12 | 0.220 |
Why?
|
| Risk Factors | 3 | 2020 | 4001 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 180 | 0.210 |
Why?
|
| Length of Stay | 2 | 2017 | 329 | 0.210 |
Why?
|
| Reoperation | 2 | 2022 | 260 | 0.200 |
Why?
|
| Pesticides | 1 | 2016 | 196 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2016 | 231 | 0.200 |
Why?
|
| Bone Density Conservation Agents | 2 | 2020 | 23 | 0.200 |
Why?
|
| Comorbidity | 3 | 2022 | 573 | 0.190 |
Why?
|
| Hypertension | 1 | 2020 | 983 | 0.190 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 240 | 0.190 |
Why?
|
| Tissue Scaffolds | 2 | 2021 | 421 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 298 | 0.190 |
Why?
|
| Obesity | 1 | 2020 | 1179 | 0.190 |
Why?
|
| Employment | 1 | 2023 | 51 | 0.190 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1152 | 0.180 |
Why?
|
| Physicians | 1 | 2024 | 165 | 0.180 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 51 | 0.180 |
Why?
|
| Medicaid | 1 | 2022 | 99 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 10 | 0.170 |
Why?
|
| Mice | 3 | 2022 | 2529 | 0.170 |
Why?
|
| Papillomaviridae | 1 | 2020 | 22 | 0.170 |
Why?
|
| Patient Care Team | 2 | 2017 | 123 | 0.170 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 67 | 0.160 |
Why?
|
| Decompression, Surgical | 1 | 2021 | 56 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 950 | 0.160 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 77 | 0.160 |
Why?
|
| Lumbar Vertebrae | 1 | 2021 | 110 | 0.160 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 1015 | 0.160 |
Why?
|
| Hispanic Americans | 1 | 2016 | 930 | 0.160 |
Why?
|
| Knee Prosthesis | 1 | 2019 | 17 | 0.150 |
Why?
|
| Prosthesis-Related Infections | 1 | 2019 | 26 | 0.150 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 122 | 0.150 |
Why?
|
| Osteoblastoma | 1 | 2019 | 1 | 0.150 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2019 | 2 | 0.150 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 42 | 0.150 |
Why?
|
| Wounds and Injuries | 1 | 2022 | 245 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 48 | 0.150 |
Why?
|
| Blood Transfusion | 1 | 2019 | 76 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 134 | 0.150 |
Why?
|
| Comprehension | 1 | 2019 | 19 | 0.150 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2018 | 5 | 0.150 |
Why?
|
| Synovitis, Pigmented Villonodular | 1 | 2018 | 6 | 0.150 |
Why?
|
| Sarcoma, Synovial | 1 | 2018 | 6 | 0.150 |
Why?
|
| Neurilemmoma | 1 | 2018 | 16 | 0.150 |
Why?
|
| Gout | 1 | 2018 | 14 | 0.150 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 20 | 0.140 |
Why?
|
| Emotions | 1 | 2019 | 59 | 0.140 |
Why?
|
| Lymphoma | 1 | 2018 | 33 | 0.140 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 14 | 0.140 |
Why?
|
| Osteoarthritis, Knee | 1 | 2019 | 82 | 0.140 |
Why?
|
| Matched-Pair Analysis | 1 | 2017 | 12 | 0.140 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 11 | 0.140 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2018 | 19 | 0.140 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2019 | 182 | 0.130 |
Why?
|
| Chondrosarcoma | 1 | 2017 | 8 | 0.130 |
Why?
|
| Cryptococcosis | 1 | 2017 | 5 | 0.130 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 17 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2017 | 99 | 0.130 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 44 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 102 | 0.130 |
Why?
|
| ROC Curve | 1 | 2017 | 169 | 0.130 |
Why?
|
| Osteomyelitis | 1 | 2017 | 29 | 0.130 |
Why?
|
| Hand | 1 | 2017 | 73 | 0.130 |
Why?
|
| Osteoarthritis | 1 | 2017 | 79 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2017 | 467 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2018 | 187 | 0.120 |
Why?
|
| Bone Density | 1 | 2018 | 203 | 0.120 |
Why?
|
| Arthroscopy | 1 | 2018 | 249 | 0.120 |
Why?
|
| Acrospiroma | 1 | 2016 | 4 | 0.120 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2016 | 7 | 0.120 |
Why?
|
| Muscle Neoplasms | 1 | 2016 | 8 | 0.120 |
Why?
|
| Mice, Inbred Strains | 1 | 2016 | 46 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 682 | 0.120 |
Why?
|
| Hindlimb | 1 | 2016 | 52 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 90 | 0.120 |
Why?
|
| Fibrosis | 1 | 2016 | 125 | 0.120 |
Why?
|
| Reference Values | 1 | 2016 | 238 | 0.110 |
Why?
|
| Logistic Models | 1 | 2017 | 783 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2022 | 469 | 0.110 |
Why?
|
| Random Allocation | 1 | 2016 | 229 | 0.110 |
Why?
|
| Carcinoma | 1 | 2016 | 92 | 0.110 |
Why?
|
| Bone Nails | 1 | 2015 | 39 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2016 | 460 | 0.110 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2015 | 38 | 0.110 |
Why?
|
| Bone Plates | 1 | 2015 | 72 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 497 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 576 | 0.110 |
Why?
|
| Radius Fractures | 1 | 2015 | 66 | 0.110 |
Why?
|
| Disease Progression | 1 | 2016 | 594 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2015 | 147 | 0.100 |
Why?
|
| Joint Instability | 1 | 2015 | 86 | 0.100 |
Why?
|
| Young Adult | 3 | 2019 | 2738 | 0.100 |
Why?
|
| Phlebography | 1 | 2012 | 26 | 0.090 |
Why?
|
| Veins | 1 | 2012 | 28 | 0.090 |
Why?
|
| Lymphocyte Activation | 1 | 2022 | 89 | 0.090 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 11 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2022 | 114 | 0.090 |
Why?
|
| Wound Infection | 1 | 2012 | 12 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2012 | 35 | 0.090 |
Why?
|
| Adolescent | 3 | 2019 | 3643 | 0.090 |
Why?
|
| Imidazoles | 1 | 2012 | 92 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 108 | 0.090 |
Why?
|
| Epithelium | 1 | 2021 | 22 | 0.090 |
Why?
|
| Gram-Negative Bacteria | 1 | 2021 | 8 | 0.090 |
Why?
|
| Radiography | 1 | 2012 | 386 | 0.080 |
Why?
|
| Ketone Bodies | 1 | 2020 | 8 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 563 | 0.080 |
Why?
|
| Mutation | 1 | 2022 | 499 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 125 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2021 | 369 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2020 | 243 | 0.070 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2018 | 19 | 0.070 |
Why?
|
| Virus Diseases | 1 | 2018 | 22 | 0.070 |
Why?
|
| Hospitalization | 2 | 2022 | 495 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2018 | 94 | 0.070 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 6 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2022 | 1852 | 0.060 |
Why?
|
| Child | 2 | 2019 | 2478 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 1309 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2017 | 52 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2018 | 413 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2017 | 181 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 81 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2018 | 604 | 0.060 |
Why?
|
| Professional Misconduct | 1 | 2024 | 3 | 0.050 |
Why?
|
| Medicine | 1 | 2024 | 40 | 0.050 |
Why?
|
| Age Factors | 1 | 2017 | 1202 | 0.050 |
Why?
|
| Trauma Centers | 1 | 2022 | 86 | 0.040 |
Why?
|
| North Carolina | 1 | 2016 | 1550 | 0.040 |
Why?
|
| Lumbosacral Region | 1 | 2021 | 11 | 0.040 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2020 | 1 | 0.040 |
Why?
|
| Germinal Center | 1 | 2020 | 5 | 0.040 |
Why?
|
| Laminectomy | 1 | 2021 | 17 | 0.040 |
Why?
|
| Diskectomy | 1 | 2021 | 18 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 14 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2020 | 11 | 0.040 |
Why?
|
| Cell Separation | 1 | 2020 | 90 | 0.040 |
Why?
|
| Spinal Fusion | 1 | 2021 | 63 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 128 | 0.040 |
Why?
|
| Bone Substitutes | 1 | 2019 | 9 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 68 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2019 | 44 | 0.040 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sclerosis | 1 | 2019 | 10 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2019 | 81 | 0.040 |
Why?
|
| Swine | 1 | 2019 | 216 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 158 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 96 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2019 | 111 | 0.040 |
Why?
|
| Curettage | 1 | 2018 | 10 | 0.040 |
Why?
|
| Bone Cements | 1 | 2018 | 11 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 241 | 0.040 |
Why?
|
| Cell Line | 1 | 2019 | 436 | 0.040 |
Why?
|
| Bone Transplantation | 1 | 2018 | 51 | 0.040 |
Why?
|
| Tibia | 1 | 2018 | 60 | 0.040 |
Why?
|
| Hepatitis C, Chronic | 1 | 2018 | 77 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 82 | 0.030 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2017 | 2 | 0.030 |
Why?
|
| Itraconazole | 1 | 2017 | 6 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2017 | 41 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 436 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 51 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2018 | 69 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 281 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 790 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 770 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 894 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 149 | 0.030 |
Why?
|
| Fractures, Closed | 1 | 2015 | 9 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 49 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 298 | 0.030 |
Why?
|
| Wrist Joint | 1 | 2015 | 60 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 526 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2019 | 659 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2015 | 195 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 238 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 396 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2015 | 193 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 252 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2287 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 2338 | 0.020 |
Why?
|